Rhenman & Partners Asset Management’s Structure Therapeutics GPCR Stock Holding History

Rhenman & Partners Asset Management’s Portfolio GPCR Stock Details GPCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$6.17M	Sell	128,100 -19,500	-13%	-$1.33M	0.76%	52
2025 Q4	$10.3M	Sell	147,600 -32,500	-18%	-$1.33M	0.96%	39
2025 Q3	$5.04M	Buy	180,100 +45,000	+33%	+$896K	0.56%	54
2025 Q2	$2.8M	Buy	135,100 +65,100	+93%	+$1.43M	0.35%	63
2025 Q1	$1.21M	Buy	+70,000	New	+$1.71M	0.14%	83

Other funds holding GPCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Rhenman & Partners Asset Management's GPCR Position: Q1 2026 in Review

Rhenman & Partners Asset Management reduced its Structure Therapeutics (GPCR) stake by 13% in Q1 2026, selling an estimated $1.33M and leaving 128,100 shares worth $6.17M. The position accounts for 0.76% of the portfolio, ranked #52.

Rhenman & Partners Asset Management first reported a position in GPCR in Q1 2025 and has held it in 5 quarters since. The position peaked at $10.3M in Q4 2025. 196 funds tracked by Wall St. Rank hold GPCR as of Q1 2026.

Rhenman & Partners Asset Management held 128,100 shares of Structure Therapeutics worth $6.17M as of Q1 2026.
Rhenman & Partners Asset Management sold 19,500 Structure Therapeutics shares in Q1 2026, an estimated $1.33M.
Structure Therapeutics made up 0.76% of Rhenman & Partners Asset Management's portfolio in Q1 2026, its #52 holding.
Rhenman & Partners Asset Management first reported a position in Structure Therapeutics in Q1 2025 and has held it in 5 quarters since.
Rhenman & Partners Asset Management's Structure Therapeutics position peaked at $10.3M in Q4 2025.
196 funds tracked by Wall St. Rank held Structure Therapeutics as of Q1 2026.

Based on Rhenman & Partners Asset Management's 13F filing for Q1 2026, filed 14 May 2026.